Validity of the third trimester ultrasound screening at 36 weeks compared to 32 weeks gestational foetus in the detection of small for gestational age
| ISRCTN | ISRCTN17997330 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17997330 |
| Protocol serial number | N/A |
| Sponsor | Hospital Sant Joan de Déu (Spain) |
| Funder | Althaia, Network Healthcare Manresa Foundation (Spain) (ref:G5828630 ) |
- Submission date
- 15/04/2011
- Registration date
- 05/12/2011
- Last edited
- 05/12/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Arquitecte Gaudí 94
Artes
08271
Spain
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled parallel study |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | A randomised controlled clinical trial on the validity of the third trimester ultrasound screening at 36 weeks compared to 32 weeks gestational foetus in the detection of small for gestational age |
| Study objectives | The studies conducted so far on the impact of routine ultrasound in the third quarter results are uncertain. According to the Cochrane meta-analysis performed by the routine ultrasound performed beyond 24 weeks gestation does not provide benefits. We interpret the studies in the context in which they were designed. Most of them differ very much in the way we act today. In addition some studies do not change the action in the diagnosis of foetal growth restriction and have no impact on perinatal outcomes, other studies if they introduce more measures to control welfare and suggest that non-detection of growth retardation leads to greater mobility and mortality. The foetuses with growth restriction have an increased risk of perinatal complications, neonatal and during adulthood. What has not been identified even if it is more sensitive at 36 than at 32 weeks following the current guidelines on gestational control. The sensitivity for detection of ultrasound foetus small for gestational age (FPEG) third quarter unselected population of pregnant women is 20% higher if they perform at 36 to 32 weeks of gestation. |
| Ethics approval(s) | Clinical Research Ethics Committee of the Union Catalan Foundation Hospitals approved on March 29th 2011 |
| Health condition(s) or problem(s) studied | Small foetuses for gestational age and intrauterine growth restriction |
| Intervention | 1. The third trimester ultrasound screening was carried out using randomisation. In the control group of pregnant women to take during the week 32 and in the case group during week 36, where static value it again foetal membranes ovulars, the foetal biometry and detection of foetal malformations, by using the calculation of weight Hadlock formula to calculate the corresponding percentile of growth. |
| Intervention type | Other |
| Primary outcome measure(s) |
1. Measurements of biparietal diameter (BPD), were obtained from a transverse axial plane of the foetal head showing a central mid-line echo broken in the anterior third by the cavum septii pellucidi and demonstrating the anterior and posterior horns of the lateral ventricles. BPD was measured from the outer borders of the skull. The hemisphere was measured from the mid-line to the inner border of the skull. |
| Key secondary outcome measure(s) |
1. The calculation of foetal weight is estimated using the formula of Hadlock 14. Formula BPD, PC, PA, LF. MA (age mesntrual) = 10.85 + 0.060 (PC) (LF) + 0.6700 (BPD) + 0.1680 (BP). With standart deviation of 1.02 and a maximum error of 3.2 weeks |
| Completion date | 01/05/2014 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Female |
| Target sample size at registration | 2600 |
| Key inclusion criteria | 1. Age greater than or equal to 18 years 2. Gestation of single foetus 3. Gestation length cranes flow dated by LCC or the first quarter 3.1. No foetal malformations detected in the first or second quarter 3.2. Absence of pregestational diabetes, renal or autoimmune diseases, chronic hypertension 4. Sign the informed consent of the study |
| Key exclusion criteria | 1. Have participated in a clinical research study during the last 3 months 2. Inability to sign informed consent or do not want to do it |
| Date of first enrolment | 01/05/2011 |
| Date of final enrolment | 01/05/2014 |
Locations
Countries of recruitment
- Spain
Study participating centre
08271
Spain
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |